RTI Biologics® Launches Fortiva™ Porcine Dermis, First Human Implantation Complete
RTI Biologics®Launches Fortiva™ Porcine Dermis, First Human Implantation Complete
Implant Rounds Out Comprehensive Line of Biologic Solutions for Hernia Repair
ALACHUA, Fla.--(BUSINESS WIRE)-- RTI Biologics Inc. (RTI) (NAS: RTIX) , a leading provider of orthopedic and other biologic implants, is pleased to announce the launch of its Fortiva™ porcine dermis implant at the Abdominal Wall Reconstruction (AWR) Conference in Washington, D.C., June 6-8. This implant positions RTI as the only provider with a comprehensive biologic solutions portfolio for use in hernia repair procedures. Tutopatch™ bovine pericardium, Tutomesh™ fenestrated bovine pericardium and Cortiva™ allograft dermis launched in March. The company's full line of implants is distributed directly by RTI's Surgical Specialties business unit.
RTI celebrated a milestone for Fortiva porcine dermis on May 23 when a patient in Missouri received a 10x16cm graft for an incisional hernia repair using a component separation technique. Due to the optimal handling characteristics of the implant, the surgeon and his staff felt the graft was easier to suture than other implants they have utilized previously, which saved time during surgery.
Fortiva porcine dermis is a non-crosslinked acellular porcine dermal matrix intended for use as a soft tissue patch to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue membranes. The implant is indicated for use in repairing hernias and/or body wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome. Fortiva porcine dermis is ready-to-use, requiring no rehydration or rinsing. Fortiva also aids in efficiency in the OR, with a temperature indicator for quick indication of proper storage, rounded corners for ease of suturing and consistent thickness. The implant is available in a broad array of sizes, including 35x35 cm, which represents the largest biologics graft available today.
Fortiva porcine dermis is sterilized through RTI's Tutoplast® Tissue Sterilization Process, a validated chemical sterilization process that thoroughly penetrates tissue, removing antigenicity and inactivating pathogens. Terminal sterilization using low dose gamma irradiation achieves a sterility assurance level (SAL) of 10-6.
"The launch of Fortiva porcine dermis is a major milestone for RTI, as we now offer surgeons the most comprehensive biologic solutions in hernia repair from a provider they trust," said Brian K. Hutchison, RTI president and CEO. "Surgeons know our company's history of reliability and safety. Fortiva gives surgeons the strength, sterility, remodeling and revascularization, and efficiency they are looking for."
RTI will be exhibiting at booth #100 at AWR. Surgeons will have the opportunity to handle some of the implants on June 8 during AWR's Masters Workshop: Hands-On Cadaver Lab. Fortiva porcine dermis will be featured at the Component Separation lab station and Tutopatch bovine pericardium will be featured at the Minimally Invasive lab station.
RTI's comprehensive line of biologic implants used in hernia repair procedures is currently available for distribution. For more information, visit www.RTIbiologics.com or contact an RTI representative at (877) 612-4287.
About RTI Biologics Inc.
RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and animal tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.
RTI's innovations continuously raise the bar of science and safety for biologics - from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. These processes — BioCleanse®, Tutoplast® and Cancelle® SP DBM — have a combined record of more than five million implants sterilized with zero incidence of implant-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.
RTI's worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.
RTI Biologics Inc.
Jenny Highlander, APR, 386-418-8888, Ext. 4149
Manager, Corporate Communications
KEYWORDS: United States North America District of Columbia Florida
The article RTI Biologics® Launches Fortiva™ Porcine Dermis, First Human Implantation Complete originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.